Initiator Pharma A/S

OM:INIT Stock Report

Market Cap: SEK 390.9m

Initiator Pharma Future Growth

Future criteria checks 6/6

Initiator Pharma is forecast to grow earnings and revenue by 31.7% and 73.9% per annum respectively. EPS is expected to grow by 30.3% per annum. Return on equity is forecast to be 31% in 3 years.

Key information

31.7%

Earnings growth rate

30.3%

EPS growth rate

Biotechs earnings growth41.0%
Revenue growth rate73.9%
Future return on equity31.0%
Analyst coverage

Low

Last updated02 Dec 2024

Recent future growth updates

Recent updates

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

May 31
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

Feb 27
Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

May 20
Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Jan 06
Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Oct 26
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Jun 12
We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Earnings and Revenue Growth Forecasts

OM:INIT - Analysts future estimates and past financials data (DKK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202652-10-11-111
12/31/20251383535351
12/31/2024N/A-16-18-181
9/30/2024N/A-11-11-11N/A
6/30/2024N/A-12-16-16N/A
3/31/2024N/A-18-19-19N/A
12/31/2023N/A-23-18-18N/A
9/30/2023N/A-27-28-28N/A
6/30/2023N/A-29-29-29N/A
3/31/2023N/A-33-30-30N/A
12/31/2022N/A-38-33-33N/A
9/30/2022N/A-40-32-32N/A
6/30/2022N/A-43-47-47N/A
3/31/2022N/A-34-40-40N/A
12/31/2021N/A-21-34-34N/A
9/30/2021N/A-16-29-29N/A
6/30/2021N/A-10-11-11N/A
3/31/2021N/A-8-10-10N/A
12/31/2020N/A-9-8-8N/A
9/30/2020N/A-10-8-8N/A
6/30/2020N/A-9-7-7N/A
3/31/2020N/A-9-8-8N/A
12/31/2019N/A-8-9-9N/A
9/30/2019N/A-7-7-7N/A
6/30/2019N/A-9-7-7N/A
3/31/2019N/A-8-10-10N/A
12/31/2018N/A-10-14-14N/A
9/30/2018N/A-13-16-16N/A
6/30/2018N/A-11N/A-14N/A
3/31/2018N/A-10N/A-11N/A
12/31/2017N/A-9N/A-8N/A
9/30/2017N/A-7N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INIT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: INIT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: INIT is expected to become profitable in the next 3 years.

Revenue vs Market: INIT's revenue (73.9% per year) is forecast to grow faster than the Swedish market (1.1% per year).

High Growth Revenue: INIT's revenue (73.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: INIT's Return on Equity is forecast to be high in 3 years time (31%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 07:11
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Initiator Pharma A/S is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Klas PalinPenser Access
Kevin SuleRedeye